(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 537.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Crinetics Pharmaceuticals's revenue in 2025 is $760,000.On average, 7 Wall Street analysts forecast CRNX's revenue for 2025 to be $482,452,670, with the lowest CRNX revenue forecast at $327,880,455, and the highest CRNX revenue forecast at $684,801,750. On average, 7 Wall Street analysts forecast CRNX's revenue for 2026 to be $5,244,682,078, with the lowest CRNX revenue forecast at $2,352,308,064, and the highest CRNX revenue forecast at $10,452,641,545.
In 2027, CRNX is forecast to generate $20,415,898,091 in revenue, with the lowest revenue forecast at $10,248,606,222 and the highest revenue forecast at $31,315,674,897.